Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Whether toripalimab plus actinomycin-D as fist-line treatment can achieve a higher complete
response rate than actinomycin-D alone.
Whether an equally high cure rate can be achieved by multi-drug chemotherapy as second-line
treatment in patients who have failed fist-line treatment with toripalimab plus
actinomycin-D.
Participants will be allocated into two groups. Those in experimental group will receive
toripalimab plus actinomycin-D, while those in control group will receive actinomycin-D
alone. Treatment will be continued until disease progression, unacceptable toxicity, or
withdrawal of consent. Treatment will be completed after 3 consolidation cycles.
Phase:
N/A
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Dalian Maternity and Child Care Hospital Gansu Provincial Maternal and Child Health Care Hospital Henan Cancer Hospital Obstetrics & Gynecology Hospital of Fudan University Shanghai Junshi Bioscience Co., Ltd. Shengjing Hospital Sichuan Cancer Hospital & Institute Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The First Affiliated Hospital of Xiamen University